The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).
 
Vaia Florou
No Relationships to Disclose
 
Charalampos S. Floudas
No Relationships to Disclose
 
Asaf Maoz
Research Funding - Johnson & Johnson/Janssen (Inst)
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Gregory Hildebrand
No Relationships to Disclose
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Garrett M. Frampton
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Umang Swami
No Relationships to Disclose
 
Breelyn A. Wilky
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Adaptimmune; Daiichi Sankyo; Deciphera; SpringWorks Therapeutics
Research Funding - Agenus
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Peter Joel Hosein
Research Funding - AngioDynamics (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Eisai (Inst); NGM Biopharmaceuticals (Inst)
 
Jonathan C. Trent
Consulting or Advisory Role - Agios; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; Epizyme; Janssen; Lilly; Novartis
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Wungki Park
Honoraria - Ipsen
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Array BioPharma; Eisai
Research Funding - ARMO BioSciences (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); Halozyme (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)